You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Facing questions over data security in the US and Ireland, the company has changed its name as it looks to shed its China operations.
CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.